KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardlytics (CDLX) Common Equity (2016 - 2025)

Historic Common Equity for Cardlytics (CDLX) over the last 10 years, with Q3 2025 value amounting to -$4.7 million.

  • Cardlytics' Common Equity fell 10674.92% to -$4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.7 million, marking a year-over-year decrease of 10674.92%. This contributed to the annual value of $70.0 million for FY2024, which is 4807.56% down from last year.
  • Latest data reveals that Cardlytics reported Common Equity of -$4.7 million as of Q3 2025, which was down 10674.92% from $58.7 million recorded in Q2 2025.
  • Cardlytics' 5-year Common Equity high stood at $744.9 million for Q1 2021, and its period low was -$4.7 million during Q3 2025.
  • For the 5-year period, Cardlytics' Common Equity averaged around $337.0 million, with its median value being $225.3 million (2023).
  • In the last 5 years, Cardlytics' Common Equity surged by 44757.37% in 2021 and then tumbled by 10674.92% in 2025.
  • Cardlytics' Common Equity (Quarter) stood at $690.7 million in 2021, then tumbled by 69.36% to $211.6 million in 2022, then crashed by 36.3% to $134.8 million in 2023, then plummeted by 48.08% to $70.0 million in 2024, then tumbled by 106.72% to -$4.7 million in 2025.
  • Its Common Equity stands at -$4.7 million for Q3 2025, versus $58.7 million for Q2 2025 and $64.1 million for Q1 2025.